Literature DB >> 16404520

Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer.

Simone Marnitz1, Christhardt Köhler, Jürgen Füller, Wolfgang Hinkelbein, Achim Schneider.   

Abstract

BACKGROUND: Simultaneous platinum-based radiochemotherapy is the standard of care for patients with advanced or node-positive cancer of the uterine cervix. A large body of literature concerning therapy-related acute and late morbidity is available. Chemoradiation-associated necrosis of the uterus has not been described so far. CASE REPORT: Two patients are reported who were treated by combined chemoradiation between 2004 and 2005 for histologically confirmed cervical cancer following laparoscopic staging. Both patients were diagnosed with squamous cell cancer of the cervix FIGO stage IIB (T2b pN1 pM1 LYM G2) and FIGO IIIA (T3a pN1 M0 G2), respectively. External-beam radiotherapy was applied in a 3-D-planned four-field technique, covering pelvic lymph nodes and primary tumor. Patient #1 received additional paraaortic irradiation. Patient #2 underwent 5 x 5 Gy brachytherapy covering the tumor. Simultaneously, cisplatin was given to both patients. Following chemoradiation, both patients developed pelvic pain and an elevation of C-reactive protein (CRP) in the presence of a normal leukocyte count. Both patients underwent relaparoscopy, and necrosis of the uterus combined with partial necrosis of the bladder was diagnosed in patient #1. Patient #1 underwent total supralevatoric exenteration and patient #2 laparoscopically assisted hysterectomy with bilateral salpingo-oophorectomy.
CONCLUSION: In patients with persisting or incident pelvic pain, questionable findings in imaging techniques and/or elevated inflammation parameters following completion of chemoradiation for cervical cancer, differential diagnosis should include radiogenic necrosis of the uterus and other pelvic organs. Laparoscopy is an ideal technique to exclude or confirm this diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16404520     DOI: 10.1007/s00066-006-1455-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  6 in total

1.  Adjuvant chemoradiation after laparoscopically assisted vaginal radical hysterectomy (LARVH) in patients with cervical cancer: oncologic outcome and morbidity.

Authors:  Arne Gruen; Thabea Musik; Christhardt Köhler; Jürgen Füller; Thomas Wendt; Carmen Stromberger; Volker Budach; Achim Schneider; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

2.  Intensity-modulated radiotherapy in patients with cervical cancer. An intra-individual comparison of prone and supine positioning.

Authors:  Carmen Stromberger; Yves Kom; Michael Kawgan-Kagan; Tristan Mensing; Ulrich Jahn; Achim Schneider; Volker Budach; Christhardt Köhler; Simone Marnitz
Journal:  Radiat Oncol       Date:  2010-07-02       Impact factor: 3.481

3.  Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin?

Authors:  Mihály Patyánik; Csaba Nemeskéri; Zsuzsa Póti; Dániel Sinkó; Csilla Pesznyák; Réka Király; Róbert Kois; Arpád Mayer
Journal:  Strahlenther Onkol       Date:  2009-09-12       Impact factor: 3.621

Review 4.  Cervical necrosis after chemoradiation for cervical cancer: case series and literature review.

Authors:  Ziad Simon Fawaz; Maroie Barkati; Marie-Claude Beauchemin; Philippe Sauthier; Philippe Gauthier; Thu Van Nguyen
Journal:  Radiat Oncol       Date:  2013-09-23       Impact factor: 3.481

5.  Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review.

Authors:  Elisabetta Sanna; Giacomo Chiappe; Fabrizio Lavra; Sonia Nemolato; Sara Oppi; Antonio Macciò; Clelia Madeddu
Journal:  Diagnostics (Basel)       Date:  2022-02-09

Review 6.  External and internal triggers of cell death in yeast.

Authors:  Claudio Falcone; Cristina Mazzoni
Journal:  Cell Mol Life Sci       Date:  2016-04-05       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.